网站地图 | 联系我们 | 新内网 | 内网登录| 留言板 | mail邮箱 | 所长信箱 | English | 中国科学院  
首页 机构设置 科研成果 研究队伍 院地合作 国际交流 研究生教育 学术出版物 党群园地 科学普及 信息公开
新闻动态
头条新闻
综合新闻
学术活动
科研动态
传媒扫描
现在位置:首页 > 新闻动态 > 学术活动
学术报告(10.11)
2016-09-30 | 作者: | 来源: | 【小  大】【打印】【关闭】

  报告题目:Targeting cancer stem cells in vivo using aptamer technology 

  报告人: Wei Duan Ph.D 

  (Professor ,School of Medicine, Deakin University, Australia) 

  报告时间:2016年10月11日上午十点 

  报告地点:西南生物多样性中心学术报告厅 

  欢迎各位有兴趣的老师和同学参加! 

  报告人简介: 

  Professor Wei Duan graduated with a MD from Shanghai University of Chinese Medicine and obtained his Ph.D. in Biochemistry and Molecular Biology at University of Melbourne in 1991. He is currently a professor of cancer therapeutics at Deakin University School of Medicine in Melbourne, Australia. 

  Prof. Duan has published more than 150 original research papers and review articles in peer-reviewed journals with an h-index of 30. His main research interest is the application of aptamer technology in targeted cancer drug delivery and molecular imaging. His work is supported by grants from National Health and Medical Research Council in Australia and Australia-Indian Strategic Research Fund ,Victoria Cancer Agency, and CASS Foundation.  

  Prof. Duan serves on the editorial board of several scientific journals, including being the Editor-in-chief of Drug Design, Development and Therapy (http://www.dovepress.com/drug-design-development-and-therapy-journal). 

  报告简介: 

  Aptamers, also known as chemical antibodies, are short single-stranded DNA or RNA that fold into complex three-dimensional structures and bind to target molecules with high affinity and specificity. Aptamers have several advantages that offer the possibility of overcoming limitations of antibodies: they have very low immunogenicity and toxicity; they display high stability at room temperature, in extreme pH, or solvent; once selected, they can be chemically synthesized free from cell-culture-derived contaminants, and they can be manufactured at any time, in large amounts, at relatively low cost and reproducibly; they are smaller and thus can diffuse more rapidly into tissues and organs and they have lower molecular weight that can lead to faster body clearance. 

  To improve cancer treatment outcome, the cancer stem cells must be effectively eliminated. However, with a few exceptions, most anticancer drugs currently on the market are incapable of eliminating cancer stem cells. Although the Nobel Prize-winning RNAi holds great potential as a cancer stem cell therapeutic, its translation into clinical medicine is hampered by the lack of an efficient in vivo delivery system. Based on our recently developed the world first RNA aptamers (chemical antibodies) against cancer stem cell surface marker proteins, we have developed a novel strategy using an all-RNA aptamer-siRNA chimera to target cancer stem cells in vivo.   Further optimisation of this platform empowered us, for the first time, to achieve cancer stem cell-targeted delivery of siRNA in mouse xenograft tumour models. This strategy can be applied to cell-targeted silencing of any disease genes in vivo.   As our system is amenable to good manufacture processes with scale-up ability, the achievement will accelerate the pace of translating RNAi technology to oncology clinics and help to realise the potential of RNAi in diseases where there are currently no drugs available.  

  动物模型与人类疾病机理重点实验室 

  肿瘤干细胞生物学学科组 

·云南实验动物网 ·“中国两栖类”信息系统 ·中国科学院科技产业网 ·灵长类动物模型学术论坛 ·政府采购机票管理网站
·云南省地方税务局发票查询 ·职工之家--工会 ·中央政府采购网 ·中国政府采购网 ·中科院昆明分院
·昆明植物研究所 ·西双版纳热带植物园 ·云南医保网 ·国家自然科学基金委员会 ·中华人民共和国科学技术部
Copyright© 2007-2016 中国科学院昆明动物研究所 .All Rights Reserved
地址:云南省昆明市教场东路32号  邮编:650223  电子邮件:zhanggq@mail.kiz.ac.cn  滇ICP备05000723号